Skip to main content
. 2021 Feb 25;22(5):2312. doi: 10.3390/ijms22052312
ATMPs Advanced Therapy Medicinal Products
CCL26 Chemokine (C-C motif) ligand 26
CCR2 C-C Chemokine Receptor Type 2
CDD Cell Delivery Device
CDH5 Cadherin 5
COX Cyclooxygenase
EC Endothelial Cell
EGR-1 Early Growth Response Protein 1
EPC Endothelial Progenitor Cells
ERK Extracellular Signal-regulated Kinases
FABP 3 Fatty Acid Binding Protein 3
Glrx Glutaredoxin-1
GM-CSF Granulocyte Macrophage-Colony-Stimulating Factor
GMP Good Manufacturing Practice
GRP78 78-kD Glucose Regulated Protein
GSH adducts S-Glutathionylation
HIF Hypoxia Inducible Factor
HSC Hematopoietic Stem Cells
IL-3 Interleukin-3
IL-8 Interleukin-8
i/nBZ Ischemic/normoxic Border Zone
IFN γ Interferon γ
M-CSF Macrophage-Colony Stimulating Factor
MSC Mesenchymal Stem Cells
MCP-1 Monocyte Chemoattractant Protein-1
MEGF10 Multiple EGF-like-domains 10
MI Myocardial infarction
miR MicroRNA
MIP-1 α Macrophage Inflammatory Protein-1α
Mreg Regulatory Macrophage
PAC Circulating Proangiogenic Cell
PAD Peripheral Arterial Disease
PCMO Programmable Cell of Monocytic Origin
PDGF Platelet Derived Growth Factor
PEG 2 Prostaglandin E 2
PI2/3K-Akt Phosphoinositide 2/3-kinases-Akt signaling pathway
PI3K Phosphoinositide 3-kinases
PTX 3 Pentraxin Related Protein 3
RIPC Remote Ischemic Preconditioning
ROI Region of Interest
SDF-1α Stromal Cell-derived Factor-1α
SMC Smooth Muscle Cells
VEGF Vascular Endothelial Growth Factor
vWF Von Willebrand Factor
Search terms
ATMPs Advanced Therapy Medicinal Products
Cardiovascular disease
Cell delivery device
Cell therapy
Cell transplantation
Cytotherapy
Ischemic microenvironment
Ischemia/reperfusion
Myocardial infarction (MI)
Peripheral arterial disease (PAD)
Stem cell therapy